Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 15/20 | 0.81 |
| ▸ | SRD5A2 | P31213 | 9/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.81 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | THPO | P40225 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294809 | 1.00 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8792952 | 0.93 | SRD5A1 (0.78) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8792956 | 0.93 | SRD5A1 (0.78) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL2297747 | 0.92 | SRD5A1 (0.82) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8749711 | 0.92 | SRD5A1 (0.82) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9621582 | 0.92 | SRD5A1 (0.82) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9134496 | 0.92 | SRD5A1 (0.82) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8793136 | 0.91 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8793134 | 0.91 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL2293256 | 0.90 | SRD5A1 (0.80) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998970-B2 | Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders | PROTEOSYS AG (DE) | 2011-08-16 | — | — | US | claimed |
| US-20090170889-A1 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS | PROTEOSYS AG (DE) | 2009-07-02 | — | — | US | claimed |
| EP-1824495-A2 | FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR PREVENTING/TREATING NEUROLOGICALLY-ASSOCIATED DISORDERS | ProteoSys AG (DE) | 2007-08-29 | — | — | EP | claimed |
| WO-2006058781-A2 | FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR PREVENTING/TREATING NEUROLOGICALLY-ASSOCIATED DISORDERS | PROTEOSYS AG (DE) | 2006-06-08 | — | — | WO | claimed |
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO., INC. | 2001-12-06 | — | — | US | claimed |
| US-6268376-B1 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2001-07-31 | — | — | US | claimed |
| EP-0859617-A1 | METHOD OF PREVENTING ANDROGENETIC ALOPECIA WITH 5-ALPHA REDUCTASE INHIBITORS | Merck & Co., Inc. (US) | 1998-08-26 | — | — | EP | claimed |
| EP-0674521-A4 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17-g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5-g(a)-ANDROST-1-EN-3-ONES. | MERCK & CO INC (US) | 1998-02-04 | — | — | EP | claimed |
| US-5629318-A | Method of treatment of chronic prostatitis with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. (US) | 1997-05-13 | — | — | US | claimed |
| WO-1997011702-A1 | METHOD OF PREVENTING ANDROGENETIC ALOPECIA WITH 5-ALPHA REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-04-03 | — | — | WO | claimed |
| EP-0547691-B1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | claimed |
| EP-0674521-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17$g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5$g(a)-ANDROST-1-EN-3-ONES | MERCK & CO. INC. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994014452-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17β-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | claimed |
| EP-0285382-B1 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-04-13 | — | — | EP | claimed |
| EP-0285383-B1 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | claimed |
| US-7998970-B2 | Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders | PROTEOSYS AG (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090170889-A1 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS | PROTEOSYS AG (DE) | 2009-07-02 | — | — | US | disclosed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | NR5A1, CYP17A1, HSD17B7 | SRD5A1 8/4885SRD5A2 11/4885LMNA 3244/4885 |
| US-20090170889-A1 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS | SLC25A4, CHRNA10, SLC25A20 | SRD5A1 511/4885SRD5A2 708/4885LMNA 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.